Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Published Online: 2023-03-?
Journal: The Lancet OncologyLoading...
Authors: Anil Kapoor•Bohuslav Melichar•Boris Alekseev•Bradley McGregor•Camillo G Porta•Carlos Alemany•Evgeny Kopyltsov•Jaime R Merchan•Jeffrey C Goh•Jodi McKenzie•Kalgi Mody•María José Méndez-Vidal•Masatoshi Eto•Michael Staehler•Naveen S Basappa•Ran Xie•Robert Motzer•Rodolfo F Perini•Se Hoon Park•Sergei Tjulandin•Sun Young Rha•Teresa Alonso Gordoa•Thomas Hutson•Thomas Powles•Tomas Buchler•Toni K Choueiri•Ugo De Giorgi•Viktor Grünwald
